FDA Proposes Sliding-Scale Paradigm For Obesity Device Trials
This article was originally published in The Gray Sheet
Executive Summary
Higher-risk devices, based on feasibility trial adverse event rates, would be matched to steeper effectiveness targets in pivotal studies for weight-loss under a plan outlined by the agency.